OBJECTIVE: To examine associations between lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) antigen level (mass) and enzymatic activity (activity) and cardiovascular disease (CVD) in older adults. METHODS: We examined associations of Lp-PLA(2) mass and activity with incident myocardial infarction (MI; n=508), stroke (n=565) and CVD death (n=665) using Cox regressions adjusted for age, sex, ethnicity and CVD risk factors in 3949 older adults, aged > or =65 years at baseline, from the Cardiovascular Health Study (CHS). RESULTS: Lp-PLA(2) was associated with incident CVD events in these older adults. Hazard ratios (95% confidence intervals) for highest versus lowest tertiles of Lp-PLA(2) mass were 1.49 (1.19-1.85) for MI, 1.21 (0.98-1.49) for stroke and 1.11 (0.92-1.33) for CVD death. The highest tertile of Lp-PLA(2) activity was associated with MI (1.36; 1.09-1.70) and CVD death (1.23; 1.02-1.50). Combined Lp-PLA(2) tertile 3 and CRP>3mg/l, compared to Lp-PLA(2) tertile 1 and CRP<1mg/l, was associated with MI (2.29; 1.49-3.52) for Lp-PLA(2) mass and MI (1.66; 1.10-2.51) and CVD death (1.57; 1.08-2.26) for activity. For MI, both mass and activity added excess risk to elevated CRP alone ( approximately 20% excess risk) and activity added excess risk for CVD death ( approximately 12%). CONCLUSION: Lp-PLA(2) mass and activity were associated with incident CVD events in older adults in CHS. Lp-PLA(2) and CRP were independent and additive in prediction of events. While associations were modest, these results support further exploration of Lp-PLA(2) to identify older individuals at risk for CVD. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
OBJECTIVE: To examine associations between lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) antigen level (mass) and enzymatic activity (activity) and cardiovascular disease (CVD) in older adults. METHODS: We examined associations of Lp-PLA(2) mass and activity with incident myocardial infarction (MI; n=508), stroke (n=565) and CVD death (n=665) using Cox regressions adjusted for age, sex, ethnicity and CVD risk factors in 3949 older adults, aged > or =65 years at baseline, from the Cardiovascular Health Study (CHS). RESULTS:Lp-PLA(2) was associated with incident CVD events in these older adults. Hazard ratios (95% confidence intervals) for highest versus lowest tertiles of Lp-PLA(2) mass were 1.49 (1.19-1.85) for MI, 1.21 (0.98-1.49) for stroke and 1.11 (0.92-1.33) for CVD death. The highest tertile of Lp-PLA(2) activity was associated with MI (1.36; 1.09-1.70) and CVD death (1.23; 1.02-1.50). Combined Lp-PLA(2) tertile 3 and CRP>3mg/l, compared to Lp-PLA(2) tertile 1 and CRP<1mg/l, was associated with MI (2.29; 1.49-3.52) for Lp-PLA(2) mass and MI (1.66; 1.10-2.51) and CVD death (1.57; 1.08-2.26) for activity. For MI, both mass and activity added excess risk to elevated CRP alone ( approximately 20% excess risk) and activity added excess risk for CVD death ( approximately 12%). CONCLUSION:Lp-PLA(2) mass and activity were associated with incident CVD events in older adults in CHS. Lp-PLA(2) and CRP were independent and additive in prediction of events. While associations were modest, these results support further exploration of Lp-PLA(2) to identify older individuals at risk for CVD. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
Authors: Allen P Burke; Andrew Farb; Joseph Pestaner; Gray T Malcom; Arthur Zieske; Robert Kutys; John Smialek; Renu Virmani Journal: Circulation Date: 2002-01-29 Impact factor: 29.690
Authors: L P Fried; N O Borhani; P Enright; C D Furberg; J M Gardin; R A Kronmal; L H Kuller; T A Manolio; M B Mittelmark; A Newman Journal: Ann Epidemiol Date: 1991-02 Impact factor: 3.797
Authors: Bruce M Psaty; Melissa Anderson; Richard A Kronmal; Russell P Tracy; Trevor Orchard; Linda P Fried; Thomas Lumley; John Robbins; Greg Burke; Anne B Newman; Curt D Furberg Journal: J Am Geriatr Soc Date: 2004-10 Impact factor: 5.562
Authors: Christie M Ballantyne; Ron C Hoogeveen; Heejung Bang; Josef Coresh; Aaron R Folsom; Gerardo Heiss; A Richey Sharrett Journal: Circulation Date: 2004-02-02 Impact factor: 29.690
Authors: Lori B Daniels; Gail A Laughlin; Mark J Sarno; Ricki Bettencourt; Robert L Wolfert; Elizabeth Barrett-Connor Journal: J Am Coll Cardiol Date: 2008-03-04 Impact factor: 24.094
Authors: Annette L Fitzpatrick; Michael C Irizarry; Mary Cushman; Nancy S Jenny; Gloria C Chi; Carol Koro Journal: Atherosclerosis Date: 2014-05-22 Impact factor: 5.162
Authors: Anna E Bortnick; Traci M Bartz; Joachim H Ix; Michel Chonchol; Alexander Reiner; Mary Cushman; David Owens; Eddy Barasch; David S Siscovick; John S Gottdiener; Jorge R Kizer Journal: Heart Date: 2016-07-13 Impact factor: 5.994
Authors: T L Nelson; M L Biggs; J R Kizer; M Cushman; J E Hokanson; C D Furberg; K J Mukamal Journal: J Clin Endocrinol Metab Date: 2012-03-07 Impact factor: 5.958
Authors: T L Nelson; A Kamineni; B Psaty; M Cushman; N S Jenny; J Hokanson; C Furberg; K J Mukamal Journal: Diabetologia Date: 2010-11-20 Impact factor: 10.122
Authors: Brian T Steffen; Lyn M Steffen; Shuang Liang; Russell Tracy; Nancy Swords Jenny; Michael Y Tsai Journal: Br J Nutr Date: 2013-04-03 Impact factor: 3.718
Authors: Ajay Nehra; Graham Jackson; Martin Miner; Kevin L Billups; Arthur L Burnett; Jacques Buvat; Culley C Carson; Glenn R Cunningham; Peter Ganz; Irwin Goldstein; Andre T Guay; Geoff Hackett; Robert A Kloner; John Kostis; Piero Montorsi; Melinda Ramsey; Raymond Rosen; Richard Sadovsky; Allen D Seftel; Ridwan Shabsigh; Charalambos Vlachopoulos; Frederick C W Wu Journal: Mayo Clin Proc Date: 2012-08 Impact factor: 7.616
Authors: Parveen K Garg; Alice M Arnold; Karen D Hinckley Stukovsky; Carol Koro; Nancy S Jenny; Kenneth J Mukamal; Michael H Criqui; Curt D Furberg; Anne B Newman; Mary Cushman Journal: Arterioscler Thromb Vasc Biol Date: 2016-02-04 Impact factor: 8.311
Authors: Nancy R Cook; Nina P Paynter; Joann E Manson; Lisa W Martin; Jennifer G Robinson; Sylvia Wassertheil-Smoller; Paul M Ridker Journal: Clin Chem Date: 2012-08-02 Impact factor: 8.327